Medical Care
Global Neurodegenerative Disease Treatment Market Research Report 2025
- Jul 08, 25
- ID: 347508
- Pages: 80
- Figures: 71
- Views: 1
The global market for Neurodegenerative Disease Treatment was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Neurodegenerative diseases largely refer to incremental damage to nerve cells in different parts of the body. These ailments, including Alzheimer’s disease, Parkinson’s disease, ADHD, and ALS, can result in loss of memory and cognitive control. While cures for such conditions are very limited, over the years, the pharmaceutical industry has released a number of treatment offerings to minimize the symptoms of neurodegenerative diseases.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Neurodegenerative Disease Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurodegenerative Disease Treatment.
The Neurodegenerative Disease Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neurodegenerative Disease Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neurodegenerative Disease Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Allergan plc
Bayer AG
F. Hoffmann La-Roche Ltd.
GlaxoSmithKline plc
Johnson & Johnson
Merck KGaA
Novartis AG
Pfizer, Inc.
Sanofi
Teva Pharmaceutical Industries Ltd.
Segment by Type
Neurotransmitter Agents
Neuroprotective Agents
Biologics
Others
Segment by Application
Multiple Sclerosis [MS]
Alzheimer’s Disease
Parkinson's Disease
Acute Migraine
Autism
Narcolepsy
Amyotrophic Lateral Sclerosis [ALS]
Attention Deficit Hyperactivity Disorder [ADHD]
Spinal Muscular Atrophy
Huntington's Disease
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neurodegenerative Disease Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Neurodegenerative diseases largely refer to incremental damage to nerve cells in different parts of the body. These ailments, including Alzheimer’s disease, Parkinson’s disease, ADHD, and ALS, can result in loss of memory and cognitive control. While cures for such conditions are very limited, over the years, the pharmaceutical industry has released a number of treatment offerings to minimize the symptoms of neurodegenerative diseases.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Neurodegenerative Disease Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurodegenerative Disease Treatment.
The Neurodegenerative Disease Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neurodegenerative Disease Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neurodegenerative Disease Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Allergan plc
Bayer AG
F. Hoffmann La-Roche Ltd.
GlaxoSmithKline plc
Johnson & Johnson
Merck KGaA
Novartis AG
Pfizer, Inc.
Sanofi
Teva Pharmaceutical Industries Ltd.
Segment by Type
Neurotransmitter Agents
Neuroprotective Agents
Biologics
Others
Segment by Application
Multiple Sclerosis [MS]
Alzheimer’s Disease
Parkinson's Disease
Acute Migraine
Autism
Narcolepsy
Amyotrophic Lateral Sclerosis [ALS]
Attention Deficit Hyperactivity Disorder [ADHD]
Spinal Muscular Atrophy
Huntington's Disease
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neurodegenerative Disease Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurodegenerative Disease Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Neurotransmitter Agents
1.2.3 Neuroprotective Agents
1.2.4 Biologics
1.2.5 Others
1.3 Market by Application
1.3.1 Global Neurodegenerative Disease Treatment Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Multiple Sclerosis MS
1.3.3 Alzheimer’s Disease
1.3.4 Parkinson's Disease
1.3.5 Acute Migraine
1.3.6 Autism
1.3.7 Narcolepsy
1.3.8 Amyotrophic Lateral Sclerosis ALS
1.3.9 Attention Deficit Hyperactivity Disorder ADHD
1.3.10 Spinal Muscular Atrophy
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neurodegenerative Disease Treatment Market Perspective (2020-2031)
2.2 Global Neurodegenerative Disease Treatment Growth Trends by Region
2.2.1 Global Neurodegenerative Disease Treatment Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Neurodegenerative Disease Treatment Historic Market Size by Region (2020-2025)
2.2.3 Neurodegenerative Disease Treatment Forecasted Market Size by Region (2026-2031)
2.3 Neurodegenerative Disease Treatment Market Dynamics
2.3.1 Neurodegenerative Disease Treatment Industry Trends
2.3.2 Neurodegenerative Disease Treatment Market Drivers
2.3.3 Neurodegenerative Disease Treatment Market Challenges
2.3.4 Neurodegenerative Disease Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neurodegenerative Disease Treatment Players by Revenue
3.1.1 Global Top Neurodegenerative Disease Treatment Players by Revenue (2020-2025)
3.1.2 Global Neurodegenerative Disease Treatment Revenue Market Share by Players (2020-2025)
3.2 Global Neurodegenerative Disease Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Neurodegenerative Disease Treatment Revenue
3.4 Global Neurodegenerative Disease Treatment Market Concentration Ratio
3.4.1 Global Neurodegenerative Disease Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Disease Treatment Revenue in 2024
3.5 Global Key Players of Neurodegenerative Disease Treatment Head office and Area Served
3.6 Global Key Players of Neurodegenerative Disease Treatment, Product and Application
3.7 Global Key Players of Neurodegenerative Disease Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Neurodegenerative Disease Treatment Breakdown Data by Type
4.1 Global Neurodegenerative Disease Treatment Historic Market Size by Type (2020-2025)
4.2 Global Neurodegenerative Disease Treatment Forecasted Market Size by Type (2026-2031)
5 Neurodegenerative Disease Treatment Breakdown Data by Application
5.1 Global Neurodegenerative Disease Treatment Historic Market Size by Application (2020-2025)
5.2 Global Neurodegenerative Disease Treatment Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Neurodegenerative Disease Treatment Market Size (2020-2031)
6.2 North America Neurodegenerative Disease Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Neurodegenerative Disease Treatment Market Size by Country (2020-2025)
6.4 North America Neurodegenerative Disease Treatment Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neurodegenerative Disease Treatment Market Size (2020-2031)
7.2 Europe Neurodegenerative Disease Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Neurodegenerative Disease Treatment Market Size by Country (2020-2025)
7.4 Europe Neurodegenerative Disease Treatment Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neurodegenerative Disease Treatment Market Size (2020-2031)
8.2 Asia-Pacific Neurodegenerative Disease Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Neurodegenerative Disease Treatment Market Size by Region (2020-2025)
8.4 Asia-Pacific Neurodegenerative Disease Treatment Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neurodegenerative Disease Treatment Market Size (2020-2031)
9.2 Latin America Neurodegenerative Disease Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Neurodegenerative Disease Treatment Market Size by Country (2020-2025)
9.4 Latin America Neurodegenerative Disease Treatment Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neurodegenerative Disease Treatment Market Size (2020-2031)
10.2 Middle East & Africa Neurodegenerative Disease Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Neurodegenerative Disease Treatment Market Size by Country (2020-2025)
10.4 Middle East & Africa Neurodegenerative Disease Treatment Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Allergan plc
11.1.1 Allergan plc Company Details
11.1.2 Allergan plc Business Overview
11.1.3 Allergan plc Neurodegenerative Disease Treatment Introduction
11.1.4 Allergan plc Revenue in Neurodegenerative Disease Treatment Business (2020-2025)
11.1.5 Allergan plc Recent Development
11.2 Bayer AG
11.2.1 Bayer AG Company Details
11.2.2 Bayer AG Business Overview
11.2.3 Bayer AG Neurodegenerative Disease Treatment Introduction
11.2.4 Bayer AG Revenue in Neurodegenerative Disease Treatment Business (2020-2025)
11.2.5 Bayer AG Recent Development
11.3 F. Hoffmann La-Roche Ltd.
11.3.1 F. Hoffmann La-Roche Ltd. Company Details
11.3.2 F. Hoffmann La-Roche Ltd. Business Overview
11.3.3 F. Hoffmann La-Roche Ltd. Neurodegenerative Disease Treatment Introduction
11.3.4 F. Hoffmann La-Roche Ltd. Revenue in Neurodegenerative Disease Treatment Business (2020-2025)
11.3.5 F. Hoffmann La-Roche Ltd. Recent Development
11.4 GlaxoSmithKline plc
11.4.1 GlaxoSmithKline plc Company Details
11.4.2 GlaxoSmithKline plc Business Overview
11.4.3 GlaxoSmithKline plc Neurodegenerative Disease Treatment Introduction
11.4.4 GlaxoSmithKline plc Revenue in Neurodegenerative Disease Treatment Business (2020-2025)
11.4.5 GlaxoSmithKline plc Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Details
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Neurodegenerative Disease Treatment Introduction
11.5.4 Johnson & Johnson Revenue in Neurodegenerative Disease Treatment Business (2020-2025)
11.5.5 Johnson & Johnson Recent Development
11.6 Merck KGaA
11.6.1 Merck KGaA Company Details
11.6.2 Merck KGaA Business Overview
11.6.3 Merck KGaA Neurodegenerative Disease Treatment Introduction
11.6.4 Merck KGaA Revenue in Neurodegenerative Disease Treatment Business (2020-2025)
11.6.5 Merck KGaA Recent Development
11.7 Novartis AG
11.7.1 Novartis AG Company Details
11.7.2 Novartis AG Business Overview
11.7.3 Novartis AG Neurodegenerative Disease Treatment Introduction
11.7.4 Novartis AG Revenue in Neurodegenerative Disease Treatment Business (2020-2025)
11.7.5 Novartis AG Recent Development
11.8 Pfizer, Inc.
11.8.1 Pfizer, Inc. Company Details
11.8.2 Pfizer, Inc. Business Overview
11.8.3 Pfizer, Inc. Neurodegenerative Disease Treatment Introduction
11.8.4 Pfizer, Inc. Revenue in Neurodegenerative Disease Treatment Business (2020-2025)
11.8.5 Pfizer, Inc. Recent Development
11.9 Sanofi
11.9.1 Sanofi Company Details
11.9.2 Sanofi Business Overview
11.9.3 Sanofi Neurodegenerative Disease Treatment Introduction
11.9.4 Sanofi Revenue in Neurodegenerative Disease Treatment Business (2020-2025)
11.9.5 Sanofi Recent Development
11.10 Teva Pharmaceutical Industries Ltd.
11.10.1 Teva Pharmaceutical Industries Ltd. Company Details
11.10.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.10.3 Teva Pharmaceutical Industries Ltd. Neurodegenerative Disease Treatment Introduction
11.10.4 Teva Pharmaceutical Industries Ltd. Revenue in Neurodegenerative Disease Treatment Business (2020-2025)
11.10.5 Teva Pharmaceutical Industries Ltd. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurodegenerative Disease Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Neurotransmitter Agents
1.2.3 Neuroprotective Agents
1.2.4 Biologics
1.2.5 Others
1.3 Market by Application
1.3.1 Global Neurodegenerative Disease Treatment Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Multiple Sclerosis MS
1.3.3 Alzheimer’s Disease
1.3.4 Parkinson's Disease
1.3.5 Acute Migraine
1.3.6 Autism
1.3.7 Narcolepsy
1.3.8 Amyotrophic Lateral Sclerosis ALS
1.3.9 Attention Deficit Hyperactivity Disorder ADHD
1.3.10 Spinal Muscular Atrophy
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neurodegenerative Disease Treatment Market Perspective (2020-2031)
2.2 Global Neurodegenerative Disease Treatment Growth Trends by Region
2.2.1 Global Neurodegenerative Disease Treatment Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Neurodegenerative Disease Treatment Historic Market Size by Region (2020-2025)
2.2.3 Neurodegenerative Disease Treatment Forecasted Market Size by Region (2026-2031)
2.3 Neurodegenerative Disease Treatment Market Dynamics
2.3.1 Neurodegenerative Disease Treatment Industry Trends
2.3.2 Neurodegenerative Disease Treatment Market Drivers
2.3.3 Neurodegenerative Disease Treatment Market Challenges
2.3.4 Neurodegenerative Disease Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neurodegenerative Disease Treatment Players by Revenue
3.1.1 Global Top Neurodegenerative Disease Treatment Players by Revenue (2020-2025)
3.1.2 Global Neurodegenerative Disease Treatment Revenue Market Share by Players (2020-2025)
3.2 Global Neurodegenerative Disease Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Neurodegenerative Disease Treatment Revenue
3.4 Global Neurodegenerative Disease Treatment Market Concentration Ratio
3.4.1 Global Neurodegenerative Disease Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Disease Treatment Revenue in 2024
3.5 Global Key Players of Neurodegenerative Disease Treatment Head office and Area Served
3.6 Global Key Players of Neurodegenerative Disease Treatment, Product and Application
3.7 Global Key Players of Neurodegenerative Disease Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Neurodegenerative Disease Treatment Breakdown Data by Type
4.1 Global Neurodegenerative Disease Treatment Historic Market Size by Type (2020-2025)
4.2 Global Neurodegenerative Disease Treatment Forecasted Market Size by Type (2026-2031)
5 Neurodegenerative Disease Treatment Breakdown Data by Application
5.1 Global Neurodegenerative Disease Treatment Historic Market Size by Application (2020-2025)
5.2 Global Neurodegenerative Disease Treatment Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Neurodegenerative Disease Treatment Market Size (2020-2031)
6.2 North America Neurodegenerative Disease Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Neurodegenerative Disease Treatment Market Size by Country (2020-2025)
6.4 North America Neurodegenerative Disease Treatment Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neurodegenerative Disease Treatment Market Size (2020-2031)
7.2 Europe Neurodegenerative Disease Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Neurodegenerative Disease Treatment Market Size by Country (2020-2025)
7.4 Europe Neurodegenerative Disease Treatment Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neurodegenerative Disease Treatment Market Size (2020-2031)
8.2 Asia-Pacific Neurodegenerative Disease Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Neurodegenerative Disease Treatment Market Size by Region (2020-2025)
8.4 Asia-Pacific Neurodegenerative Disease Treatment Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neurodegenerative Disease Treatment Market Size (2020-2031)
9.2 Latin America Neurodegenerative Disease Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Neurodegenerative Disease Treatment Market Size by Country (2020-2025)
9.4 Latin America Neurodegenerative Disease Treatment Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neurodegenerative Disease Treatment Market Size (2020-2031)
10.2 Middle East & Africa Neurodegenerative Disease Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Neurodegenerative Disease Treatment Market Size by Country (2020-2025)
10.4 Middle East & Africa Neurodegenerative Disease Treatment Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Allergan plc
11.1.1 Allergan plc Company Details
11.1.2 Allergan plc Business Overview
11.1.3 Allergan plc Neurodegenerative Disease Treatment Introduction
11.1.4 Allergan plc Revenue in Neurodegenerative Disease Treatment Business (2020-2025)
11.1.5 Allergan plc Recent Development
11.2 Bayer AG
11.2.1 Bayer AG Company Details
11.2.2 Bayer AG Business Overview
11.2.3 Bayer AG Neurodegenerative Disease Treatment Introduction
11.2.4 Bayer AG Revenue in Neurodegenerative Disease Treatment Business (2020-2025)
11.2.5 Bayer AG Recent Development
11.3 F. Hoffmann La-Roche Ltd.
11.3.1 F. Hoffmann La-Roche Ltd. Company Details
11.3.2 F. Hoffmann La-Roche Ltd. Business Overview
11.3.3 F. Hoffmann La-Roche Ltd. Neurodegenerative Disease Treatment Introduction
11.3.4 F. Hoffmann La-Roche Ltd. Revenue in Neurodegenerative Disease Treatment Business (2020-2025)
11.3.5 F. Hoffmann La-Roche Ltd. Recent Development
11.4 GlaxoSmithKline plc
11.4.1 GlaxoSmithKline plc Company Details
11.4.2 GlaxoSmithKline plc Business Overview
11.4.3 GlaxoSmithKline plc Neurodegenerative Disease Treatment Introduction
11.4.4 GlaxoSmithKline plc Revenue in Neurodegenerative Disease Treatment Business (2020-2025)
11.4.5 GlaxoSmithKline plc Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Details
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Neurodegenerative Disease Treatment Introduction
11.5.4 Johnson & Johnson Revenue in Neurodegenerative Disease Treatment Business (2020-2025)
11.5.5 Johnson & Johnson Recent Development
11.6 Merck KGaA
11.6.1 Merck KGaA Company Details
11.6.2 Merck KGaA Business Overview
11.6.3 Merck KGaA Neurodegenerative Disease Treatment Introduction
11.6.4 Merck KGaA Revenue in Neurodegenerative Disease Treatment Business (2020-2025)
11.6.5 Merck KGaA Recent Development
11.7 Novartis AG
11.7.1 Novartis AG Company Details
11.7.2 Novartis AG Business Overview
11.7.3 Novartis AG Neurodegenerative Disease Treatment Introduction
11.7.4 Novartis AG Revenue in Neurodegenerative Disease Treatment Business (2020-2025)
11.7.5 Novartis AG Recent Development
11.8 Pfizer, Inc.
11.8.1 Pfizer, Inc. Company Details
11.8.2 Pfizer, Inc. Business Overview
11.8.3 Pfizer, Inc. Neurodegenerative Disease Treatment Introduction
11.8.4 Pfizer, Inc. Revenue in Neurodegenerative Disease Treatment Business (2020-2025)
11.8.5 Pfizer, Inc. Recent Development
11.9 Sanofi
11.9.1 Sanofi Company Details
11.9.2 Sanofi Business Overview
11.9.3 Sanofi Neurodegenerative Disease Treatment Introduction
11.9.4 Sanofi Revenue in Neurodegenerative Disease Treatment Business (2020-2025)
11.9.5 Sanofi Recent Development
11.10 Teva Pharmaceutical Industries Ltd.
11.10.1 Teva Pharmaceutical Industries Ltd. Company Details
11.10.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.10.3 Teva Pharmaceutical Industries Ltd. Neurodegenerative Disease Treatment Introduction
11.10.4 Teva Pharmaceutical Industries Ltd. Revenue in Neurodegenerative Disease Treatment Business (2020-2025)
11.10.5 Teva Pharmaceutical Industries Ltd. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Neurodegenerative Disease Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Neurotransmitter Agents
Table 3. Key Players of Neuroprotective Agents
Table 4. Key Players of Biologics
Table 5. Key Players of Others
Table 6. Global Neurodegenerative Disease Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Neurodegenerative Disease Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Neurodegenerative Disease Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Neurodegenerative Disease Treatment Market Share by Region (2020-2025)
Table 10. Global Neurodegenerative Disease Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Neurodegenerative Disease Treatment Market Share by Region (2026-2031)
Table 12. Neurodegenerative Disease Treatment Market Trends
Table 13. Neurodegenerative Disease Treatment Market Drivers
Table 14. Neurodegenerative Disease Treatment Market Challenges
Table 15. Neurodegenerative Disease Treatment Market Restraints
Table 16. Global Neurodegenerative Disease Treatment Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Neurodegenerative Disease Treatment Market Share by Players (2020-2025)
Table 18. Global Top Neurodegenerative Disease Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disease Treatment as of 2024)
Table 19. Ranking of Global Top Neurodegenerative Disease Treatment Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Neurodegenerative Disease Treatment Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Neurodegenerative Disease Treatment, Headquarters and Area Served
Table 22. Global Key Players of Neurodegenerative Disease Treatment, Product and Application
Table 23. Global Key Players of Neurodegenerative Disease Treatment, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Neurodegenerative Disease Treatment Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Neurodegenerative Disease Treatment Revenue Market Share by Type (2020-2025)
Table 27. Global Neurodegenerative Disease Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Neurodegenerative Disease Treatment Revenue Market Share by Type (2026-2031)
Table 29. Global Neurodegenerative Disease Treatment Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Neurodegenerative Disease Treatment Revenue Market Share by Application (2020-2025)
Table 31. Global Neurodegenerative Disease Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Neurodegenerative Disease Treatment Revenue Market Share by Application (2026-2031)
Table 33. North America Neurodegenerative Disease Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Neurodegenerative Disease Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Neurodegenerative Disease Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Neurodegenerative Disease Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Neurodegenerative Disease Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Neurodegenerative Disease Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Neurodegenerative Disease Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Neurodegenerative Disease Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Neurodegenerative Disease Treatment Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Neurodegenerative Disease Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Neurodegenerative Disease Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Neurodegenerative Disease Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Neurodegenerative Disease Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Neurodegenerative Disease Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Neurodegenerative Disease Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 48. Allergan plc Company Details
Table 49. Allergan plc Business Overview
Table 50. Allergan plc Neurodegenerative Disease Treatment Product
Table 51. Allergan plc Revenue in Neurodegenerative Disease Treatment Business (2020-2025) & (US$ Million)
Table 52. Allergan plc Recent Development
Table 53. Bayer AG Company Details
Table 54. Bayer AG Business Overview
Table 55. Bayer AG Neurodegenerative Disease Treatment Product
Table 56. Bayer AG Revenue in Neurodegenerative Disease Treatment Business (2020-2025) & (US$ Million)
Table 57. Bayer AG Recent Development
Table 58. F. Hoffmann La-Roche Ltd. Company Details
Table 59. F. Hoffmann La-Roche Ltd. Business Overview
Table 60. F. Hoffmann La-Roche Ltd. Neurodegenerative Disease Treatment Product
Table 61. F. Hoffmann La-Roche Ltd. Revenue in Neurodegenerative Disease Treatment Business (2020-2025) & (US$ Million)
Table 62. F. Hoffmann La-Roche Ltd. Recent Development
Table 63. GlaxoSmithKline plc Company Details
Table 64. GlaxoSmithKline plc Business Overview
Table 65. GlaxoSmithKline plc Neurodegenerative Disease Treatment Product
Table 66. GlaxoSmithKline plc Revenue in Neurodegenerative Disease Treatment Business (2020-2025) & (US$ Million)
Table 67. GlaxoSmithKline plc Recent Development
Table 68. Johnson & Johnson Company Details
Table 69. Johnson & Johnson Business Overview
Table 70. Johnson & Johnson Neurodegenerative Disease Treatment Product
Table 71. Johnson & Johnson Revenue in Neurodegenerative Disease Treatment Business (2020-2025) & (US$ Million)
Table 72. Johnson & Johnson Recent Development
Table 73. Merck KGaA Company Details
Table 74. Merck KGaA Business Overview
Table 75. Merck KGaA Neurodegenerative Disease Treatment Product
Table 76. Merck KGaA Revenue in Neurodegenerative Disease Treatment Business (2020-2025) & (US$ Million)
Table 77. Merck KGaA Recent Development
Table 78. Novartis AG Company Details
Table 79. Novartis AG Business Overview
Table 80. Novartis AG Neurodegenerative Disease Treatment Product
Table 81. Novartis AG Revenue in Neurodegenerative Disease Treatment Business (2020-2025) & (US$ Million)
Table 82. Novartis AG Recent Development
Table 83. Pfizer, Inc. Company Details
Table 84. Pfizer, Inc. Business Overview
Table 85. Pfizer, Inc. Neurodegenerative Disease Treatment Product
Table 86. Pfizer, Inc. Revenue in Neurodegenerative Disease Treatment Business (2020-2025) & (US$ Million)
Table 87. Pfizer, Inc. Recent Development
Table 88. Sanofi Company Details
Table 89. Sanofi Business Overview
Table 90. Sanofi Neurodegenerative Disease Treatment Product
Table 91. Sanofi Revenue in Neurodegenerative Disease Treatment Business (2020-2025) & (US$ Million)
Table 92. Sanofi Recent Development
Table 93. Teva Pharmaceutical Industries Ltd. Company Details
Table 94. Teva Pharmaceutical Industries Ltd. Business Overview
Table 95. Teva Pharmaceutical Industries Ltd. Neurodegenerative Disease Treatment Product
Table 96. Teva Pharmaceutical Industries Ltd. Revenue in Neurodegenerative Disease Treatment Business (2020-2025) & (US$ Million)
Table 97. Teva Pharmaceutical Industries Ltd. Recent Development
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
Table 101. Authors List of This Report
List of Figures
Figure 1. Neurodegenerative Disease Treatment Picture
Figure 2. Global Neurodegenerative Disease Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Neurodegenerative Disease Treatment Market Share by Type: 2024 VS 2031
Figure 4. Neurotransmitter Agents Features
Figure 5. Neuroprotective Agents Features
Figure 6. Biologics Features
Figure 7. Others Features
Figure 8. Global Neurodegenerative Disease Treatment Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Neurodegenerative Disease Treatment Market Share by Application: 2024 VS 2031
Figure 10. Multiple Sclerosis MS Case Studies
Figure 11. Alzheimer’s Disease Case Studies
Figure 12. Parkinson's Disease Case Studies
Figure 13. Acute Migraine Case Studies
Figure 14. Autism Case Studies
Figure 15. Narcolepsy Case Studies
Figure 16. Amyotrophic Lateral Sclerosis ALS Case Studies
Figure 17. Attention Deficit Hyperactivity Disorder ADHD Case Studies
Figure 18. Spinal Muscular Atrophy Case Studies
Figure 19. Neurodegenerative Disease Treatment Report Years Considered
Figure 20. Global Neurodegenerative Disease Treatment Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 21. Global Neurodegenerative Disease Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 22. Global Neurodegenerative Disease Treatment Market Share by Region: 2024 VS 2031
Figure 23. Global Neurodegenerative Disease Treatment Market Share by Players in 2024
Figure 24. Global Top Neurodegenerative Disease Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disease Treatment as of 2024)
Figure 25. The Top 10 and 5 Players Market Share by Neurodegenerative Disease Treatment Revenue in 2024
Figure 26. North America Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. North America Neurodegenerative Disease Treatment Market Share by Country (2020-2031)
Figure 28. United States Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Canada Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Europe Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Europe Neurodegenerative Disease Treatment Market Share by Country (2020-2031)
Figure 32. Germany Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. France Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. U.K. Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Italy Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Russia Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Nordic Countries Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Asia-Pacific Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Asia-Pacific Neurodegenerative Disease Treatment Market Share by Region (2020-2031)
Figure 40. China Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Japan Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. South Korea Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Southeast Asia Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. India Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Australia Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Latin America Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Latin America Neurodegenerative Disease Treatment Market Share by Country (2020-2031)
Figure 48. Mexico Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Brazil Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Middle East & Africa Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Middle East & Africa Neurodegenerative Disease Treatment Market Share by Country (2020-2031)
Figure 52. Turkey Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 53. Saudi Arabia Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 54. UAE Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 55. Allergan plc Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2020-2025)
Figure 56. Bayer AG Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2020-2025)
Figure 57. F. Hoffmann La-Roche Ltd. Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2020-2025)
Figure 58. GlaxoSmithKline plc Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2020-2025)
Figure 59. Johnson & Johnson Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2020-2025)
Figure 60. Merck KGaA Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2020-2025)
Figure 61. Novartis AG Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2020-2025)
Figure 62. Pfizer, Inc. Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2020-2025)
Figure 63. Sanofi Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2020-2025)
Figure 64. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2020-2025)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Table 1. Global Neurodegenerative Disease Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Neurotransmitter Agents
Table 3. Key Players of Neuroprotective Agents
Table 4. Key Players of Biologics
Table 5. Key Players of Others
Table 6. Global Neurodegenerative Disease Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Neurodegenerative Disease Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Neurodegenerative Disease Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Neurodegenerative Disease Treatment Market Share by Region (2020-2025)
Table 10. Global Neurodegenerative Disease Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Neurodegenerative Disease Treatment Market Share by Region (2026-2031)
Table 12. Neurodegenerative Disease Treatment Market Trends
Table 13. Neurodegenerative Disease Treatment Market Drivers
Table 14. Neurodegenerative Disease Treatment Market Challenges
Table 15. Neurodegenerative Disease Treatment Market Restraints
Table 16. Global Neurodegenerative Disease Treatment Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Neurodegenerative Disease Treatment Market Share by Players (2020-2025)
Table 18. Global Top Neurodegenerative Disease Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disease Treatment as of 2024)
Table 19. Ranking of Global Top Neurodegenerative Disease Treatment Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Neurodegenerative Disease Treatment Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Neurodegenerative Disease Treatment, Headquarters and Area Served
Table 22. Global Key Players of Neurodegenerative Disease Treatment, Product and Application
Table 23. Global Key Players of Neurodegenerative Disease Treatment, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Neurodegenerative Disease Treatment Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Neurodegenerative Disease Treatment Revenue Market Share by Type (2020-2025)
Table 27. Global Neurodegenerative Disease Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Neurodegenerative Disease Treatment Revenue Market Share by Type (2026-2031)
Table 29. Global Neurodegenerative Disease Treatment Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Neurodegenerative Disease Treatment Revenue Market Share by Application (2020-2025)
Table 31. Global Neurodegenerative Disease Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Neurodegenerative Disease Treatment Revenue Market Share by Application (2026-2031)
Table 33. North America Neurodegenerative Disease Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Neurodegenerative Disease Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Neurodegenerative Disease Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Neurodegenerative Disease Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Neurodegenerative Disease Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Neurodegenerative Disease Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Neurodegenerative Disease Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Neurodegenerative Disease Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Neurodegenerative Disease Treatment Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Neurodegenerative Disease Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Neurodegenerative Disease Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Neurodegenerative Disease Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Neurodegenerative Disease Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Neurodegenerative Disease Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Neurodegenerative Disease Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 48. Allergan plc Company Details
Table 49. Allergan plc Business Overview
Table 50. Allergan plc Neurodegenerative Disease Treatment Product
Table 51. Allergan plc Revenue in Neurodegenerative Disease Treatment Business (2020-2025) & (US$ Million)
Table 52. Allergan plc Recent Development
Table 53. Bayer AG Company Details
Table 54. Bayer AG Business Overview
Table 55. Bayer AG Neurodegenerative Disease Treatment Product
Table 56. Bayer AG Revenue in Neurodegenerative Disease Treatment Business (2020-2025) & (US$ Million)
Table 57. Bayer AG Recent Development
Table 58. F. Hoffmann La-Roche Ltd. Company Details
Table 59. F. Hoffmann La-Roche Ltd. Business Overview
Table 60. F. Hoffmann La-Roche Ltd. Neurodegenerative Disease Treatment Product
Table 61. F. Hoffmann La-Roche Ltd. Revenue in Neurodegenerative Disease Treatment Business (2020-2025) & (US$ Million)
Table 62. F. Hoffmann La-Roche Ltd. Recent Development
Table 63. GlaxoSmithKline plc Company Details
Table 64. GlaxoSmithKline plc Business Overview
Table 65. GlaxoSmithKline plc Neurodegenerative Disease Treatment Product
Table 66. GlaxoSmithKline plc Revenue in Neurodegenerative Disease Treatment Business (2020-2025) & (US$ Million)
Table 67. GlaxoSmithKline plc Recent Development
Table 68. Johnson & Johnson Company Details
Table 69. Johnson & Johnson Business Overview
Table 70. Johnson & Johnson Neurodegenerative Disease Treatment Product
Table 71. Johnson & Johnson Revenue in Neurodegenerative Disease Treatment Business (2020-2025) & (US$ Million)
Table 72. Johnson & Johnson Recent Development
Table 73. Merck KGaA Company Details
Table 74. Merck KGaA Business Overview
Table 75. Merck KGaA Neurodegenerative Disease Treatment Product
Table 76. Merck KGaA Revenue in Neurodegenerative Disease Treatment Business (2020-2025) & (US$ Million)
Table 77. Merck KGaA Recent Development
Table 78. Novartis AG Company Details
Table 79. Novartis AG Business Overview
Table 80. Novartis AG Neurodegenerative Disease Treatment Product
Table 81. Novartis AG Revenue in Neurodegenerative Disease Treatment Business (2020-2025) & (US$ Million)
Table 82. Novartis AG Recent Development
Table 83. Pfizer, Inc. Company Details
Table 84. Pfizer, Inc. Business Overview
Table 85. Pfizer, Inc. Neurodegenerative Disease Treatment Product
Table 86. Pfizer, Inc. Revenue in Neurodegenerative Disease Treatment Business (2020-2025) & (US$ Million)
Table 87. Pfizer, Inc. Recent Development
Table 88. Sanofi Company Details
Table 89. Sanofi Business Overview
Table 90. Sanofi Neurodegenerative Disease Treatment Product
Table 91. Sanofi Revenue in Neurodegenerative Disease Treatment Business (2020-2025) & (US$ Million)
Table 92. Sanofi Recent Development
Table 93. Teva Pharmaceutical Industries Ltd. Company Details
Table 94. Teva Pharmaceutical Industries Ltd. Business Overview
Table 95. Teva Pharmaceutical Industries Ltd. Neurodegenerative Disease Treatment Product
Table 96. Teva Pharmaceutical Industries Ltd. Revenue in Neurodegenerative Disease Treatment Business (2020-2025) & (US$ Million)
Table 97. Teva Pharmaceutical Industries Ltd. Recent Development
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
Table 101. Authors List of This Report
List of Figures
Figure 1. Neurodegenerative Disease Treatment Picture
Figure 2. Global Neurodegenerative Disease Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Neurodegenerative Disease Treatment Market Share by Type: 2024 VS 2031
Figure 4. Neurotransmitter Agents Features
Figure 5. Neuroprotective Agents Features
Figure 6. Biologics Features
Figure 7. Others Features
Figure 8. Global Neurodegenerative Disease Treatment Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Neurodegenerative Disease Treatment Market Share by Application: 2024 VS 2031
Figure 10. Multiple Sclerosis MS Case Studies
Figure 11. Alzheimer’s Disease Case Studies
Figure 12. Parkinson's Disease Case Studies
Figure 13. Acute Migraine Case Studies
Figure 14. Autism Case Studies
Figure 15. Narcolepsy Case Studies
Figure 16. Amyotrophic Lateral Sclerosis ALS Case Studies
Figure 17. Attention Deficit Hyperactivity Disorder ADHD Case Studies
Figure 18. Spinal Muscular Atrophy Case Studies
Figure 19. Neurodegenerative Disease Treatment Report Years Considered
Figure 20. Global Neurodegenerative Disease Treatment Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 21. Global Neurodegenerative Disease Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 22. Global Neurodegenerative Disease Treatment Market Share by Region: 2024 VS 2031
Figure 23. Global Neurodegenerative Disease Treatment Market Share by Players in 2024
Figure 24. Global Top Neurodegenerative Disease Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disease Treatment as of 2024)
Figure 25. The Top 10 and 5 Players Market Share by Neurodegenerative Disease Treatment Revenue in 2024
Figure 26. North America Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. North America Neurodegenerative Disease Treatment Market Share by Country (2020-2031)
Figure 28. United States Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Canada Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Europe Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Europe Neurodegenerative Disease Treatment Market Share by Country (2020-2031)
Figure 32. Germany Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. France Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. U.K. Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Italy Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Russia Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Nordic Countries Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Asia-Pacific Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Asia-Pacific Neurodegenerative Disease Treatment Market Share by Region (2020-2031)
Figure 40. China Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Japan Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. South Korea Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Southeast Asia Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. India Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Australia Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Latin America Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Latin America Neurodegenerative Disease Treatment Market Share by Country (2020-2031)
Figure 48. Mexico Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Brazil Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Middle East & Africa Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Middle East & Africa Neurodegenerative Disease Treatment Market Share by Country (2020-2031)
Figure 52. Turkey Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 53. Saudi Arabia Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 54. UAE Neurodegenerative Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 55. Allergan plc Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2020-2025)
Figure 56. Bayer AG Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2020-2025)
Figure 57. F. Hoffmann La-Roche Ltd. Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2020-2025)
Figure 58. GlaxoSmithKline plc Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2020-2025)
Figure 59. Johnson & Johnson Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2020-2025)
Figure 60. Merck KGaA Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2020-2025)
Figure 61. Novartis AG Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2020-2025)
Figure 62. Pfizer, Inc. Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2020-2025)
Figure 63. Sanofi Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2020-2025)
Figure 64. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Neurodegenerative Disease Treatment Business (2020-2025)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Electrolytes for Lithium-Ion Batteries Market Research Report 2025
Jul 14, 25
Global Vanadium Products Market Research Report 2025
Jul 14, 25
Global High-purity Vanadium Oxide Market Research Report 2025
Jul 14, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232